Evidence map›Paper›PMID 24734094›Full record

ArticleHepatitis monthly2014

Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis.

Alessandro Federico, Dolores Sgambato, Gaetano Cotticelli, Antonietta Gerarda Gravina, Marcello Dallio, Filippo Beneduce, Eleonora Ruocco, Marco Romano, Carmela Loguercio

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatitis monthly, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alessandro FedericoDepartment of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy.
Dolores SgambatoDepartment of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy.
Gaetano CotticelliDepartment of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy.
Antonietta Gerarda GravinaDepartment of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy.
Marcello DallioDepartment of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy.
Filippo BeneduceDepartment of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy.
Eleonora RuoccoDepartment of Dermatology, Second University of Naples, Naples, Italy.
Marco RomanoDepartment of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy.
Carmela LoguercioDepartment of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy.
University of Campania "Luigi Vanvitelli" · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDermatological adverse events are an existing concern during treatment of hepatitis C virus infection. Peginterferon/ribavirin treatment is associated with well-characterized dermatological lesions tending towards a uniform entity of dermatitis. New telaprevir- or boceprevir-based triple-therapy has led to significant improvements in sustained virological response rates, although associated with an increase in cutaneous adverse events compared peginterferon/ribavirin alone. CASE PRESENTATION: We report a case of a patient who discontinued telaprevir because of severe skin eruptions and who, during ribavirin and interferon treatment, after a period free of skin lesions, developed new dermatological lesions different than those experienced during telaprevir treatment.

conclusionsSeveral adverse effects are associated to anti-HCV drugs, hence appropriate skin care management and follow-up are very important. A careful anamnesis before the initiation of triple therapy is necessary to identify previous dermatological diseases that could increase skin adverse effects incidence.

Indexed as

Liver CirrhosisSkin DiseasesTelaprevir

Identifiers

PMID24734094
PMCPMC3984470
OpenAlexW2150645913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.